Gyros has announced that Cygnus Technologies and Radix Biosolutions have launched kits specifically designed for compatibility with the company's immunoassay platform.
The kits are intended to save time and labour during biotherapeutic development and production.
Cygnus Technologies provides analytical products to the pharmaceutical and biotechnology industry for testing biologics and their impurities during process development and quality control.
The two new Cygnus kits have been developed to test for impurities, namely host cell proteins from CHO and E coli.
Scientists optimising purification processes and working in process control, routine QC and product release testing will benefit from the convenience of ready-to-use kits while maximising their efficiency by utilising the automated immunoassay platform from Gyros.
At Radix Biosolutions, a US-based contract research organisation specialising in custom assay development and reagent manufacturing, the Gyrolab xP workstation is used in development programmes.
The goal of the new immunoassay kit is to provide analytical measurements for customers that need to evaluate the pharmacokinetics of their antibody-based biotherapeutics in low-volume samples.
The kit has been developed under fit-for-purpose standards and the core principles of the 21st Century Bioanalytical Lab Initiative to ensure highest performance and facilitate lab-to-lab harmonisation.
